Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Methyl Salicylate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | CA1 | P00915 | 4/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | CA9 | Q16790 | 4/20 | 0.61 |
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Salicylate SCHEMBL1872042 | 0.92 | LMNA (1.00) | TSHRLMNACA1CA2CA9 | |
| Methyl Salicylate SCHEMBL29370254 | 0.92 | LMNA (1.00) | TSHRLMNACA1CA2CA9 | |
| Methyl Salicylate SCHEMBL5312 | 0.92 | LMNA (1.00) | TSHRLMNACA1CA2CA9 | |
| Methyl Salicylate SCHEMBL7961798 | 0.90 | LMNA (0.96) | TSHRLMNACA1CA2CA9 | |
| Methyl Salicylate SCHEMBL7961805 | 0.90 | LMNA (0.96) | TSHRLMNACA1CA2CA9 | |
| Methyl Salicylate SCHEMBL23045204 | 0.90 | LMNA (0.96) | TSHRLMNACA1CA2CA9 | |
| Methyl Salicylate SCHEMBL30721422 | 0.90 | LMNA (0.96) | TSHRLMNACA1CA2CA9 | |
| Methyl Salicylate SCHEMBL416476 | 0.90 | LMNA (0.96) | TSHRLMNACA1CA2CA9 | |
| Methyl Salicylate SCHEMBL5795853 | 0.90 | LMNA (0.96) | TSHRLMNACA1CA2CA9 | |
| Methyl Salicylate SCHEMBL29020443 | 0.90 | LMNA (0.96) | TSHRLMNACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081914-A1 | PROCESS FOR THE PREPARATION OF BENZO [D] ISOXAZOL-3-YL-METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF | DIPHARMA S.P.A. (IT) | 2008-04-03 | — | — | US | disclosed |
| US-7291742-B2 | Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof | DIPHARMA S.P.A. (IT) | 2007-11-06 | — | — | US | disclosed |
| US-20060135582-A1 | Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof | DIPHARMA S.P.A. (IT) | 2006-06-22 | — | — | US | disclosed |
| EP-1581508-A1 | A PROCESS FOR THE PREPARATION OF BENZO D ISOXAZOL-3-YL- METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF | Dipharma S.p.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063173-A1 | A PROCESS FOR THE PREPARATION OF BENZO[D]ISOXAZOL-3-YL-METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF | DIPHARMA S.P.A. (IT) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081914-A1 | PROCESS FOR THE PREPARATION OF BENZO [D] ISOXAZOL-3-YL-METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF | GABRD, GABRA5, GABRA6 | EGFR 4396/4885TSHR 3449/4885LMNA 1596/4885 |
| US-20060135582-A1 | Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof | GABRD, GABRA5, GABRA6 | EGFR 4396/4885TSHR 3449/4885LMNA 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.